{"id":576277,"date":"2021-11-23T15:24:01","date_gmt":"2021-11-23T15:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=576277"},"modified":"2021-11-23T15:24:01","modified_gmt":"2021-11-23T15:24:01","slug":"the-bipolar-depression-market-is-growing-at-a-cagr-of-119-driven-by-the-potential-pipeline-therapies-during-the-study-period-201730-in-the-7mm","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/the-bipolar-depression-market-is-growing-at-a-cagr-of-119-driven-by-the-potential-pipeline-therapies-during-the-study-period-201730-in-the-7mm_576277.html","title":{"rendered":"The Bipolar Depression market is growing at a CAGR of 11.9%, driven by the potential pipeline therapies during the study period (2017-30) in the 7MM"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1637648970.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"The Bipolar Depression market is growing at a CAGR of 11.9%, driven by the potential pipeline therapies during the study period (2017-30) in the 7MM\" src=\"https:\/\/www.abnewswire.com\/uploads\/1637648970.png\" alt=\"The Bipolar Depression market is growing at a CAGR of 11.9%, driven by the potential pipeline therapies during the study period (2017-30) in the 7MM\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Bipolar Depression Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Bipolar Depression treatment space will see a significant impact in the coming years as treatment improves over time along with the launch of novel therapies.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/881f27ee21fa9823660ca6a1ca4b6dba.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bipolar-disorder-manic-depression-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Bipolar Depression market report<\/a><\/strong> provides thorough comprehension of Bipolar Depression, historical and forecasted epidemiology, and Bipolar Depression market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Takeaways from the Bipolar Depression Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to the National Institute of Mental Health (NIMH), a branch of the National Institutes of Health, the 12-month prevalence of bipolar disorder among US adults aged 18 and older was found to be 2.8% based on diagnostic interview data from the National Comorbidity Survey Replication (NCS-R). It also stated that an estimated <strong>4.4%<\/strong> of adults in the United States have bipolar disorder at some point in their lives.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">As per DelveInsight estimates, the total Bipolar Depression diagnosed prevalent cases were <strong>2,401,287<\/strong> in the US in 2020, which is further expected to increase by 2030.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">As per the estimates, the highest Bipolar Depression prevalent cases were of <strong>severe cases<\/strong> followed by moderate and mild in the UK in 2020.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The leading pharma companies developing therapies to improve the Bipolar Depression treatment landscape include <strong>Intra-Cellular Therapies, NeuroRx, Otsuka, Lundbeck, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, Celon Pharma,<\/strong> and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Bipolar Depression therapies in the pipeline include <strong>Caplyta (Lumateperone; ITI-007), NRX-100\/NRX-101, Rexulti\/Rxulti (Brexpiprazole), SEP-4199, COMP 360 (Psilocybin Therapy), Falkieri (Esketamine DPI),<\/strong> and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>NeuroRx<\/strong> has developed a sequential therapy that consists of intravenous <strong>NRX-100 (ketamine HCL)<\/strong> for rapid stabilisation of depression and suicidal ideation, followed by oral NRX-101 (fixed-dose combination of D-cycloserine and lurasidone) for maintenance of stabilisation from depression and suicidal ideation symptoms.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>SEP-4199 (Sunovion)<\/strong> is a non-racemic ratio of amisulpride enantiomers that has the potential to be the first benzamide treatment for mood disorders available in the United States.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Bipolar Depression market size is anticipated to grow at a <strong>CAGR of 11.9%<\/strong> during the study period (2017-30).<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Want to learn more? Request for sample @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bipolar-disorder-manic-depression-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Bipolar Depression Market Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bipolar Depression: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Bipolar Disorder (BD) is a mental illness marked by mood swings between depression and mania. BD is classified into four types based on the characteristics of the episodes: BD-I, BD-II, cyclothymic disorder, and bipolar disorder not otherwise specified (NOS).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bipolar Depression Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Bipolar Depression report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bipolar Depression Total Diagnosed Prevalent Cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bipolar Depression Type-Specific Diagnosed Prevalent Cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bipolar Depression Severity-Specific Diagnosed Prevalent Cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bipolar Depression Total Treated Cases<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bipolar Depression Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Bipolar Depression treatment&#8217;s ultimate goal is to achieve a high level of psychosocial function and health-related quality of life. For bipolar depression patients, several off-label uses of therapies, or combinatorial therapy, are common. <strong>Anticonvulsants (such as Divalproex and Lamotrigine), Olanzapine monotherapy, and combined lithium and lamotrigine therapy<\/strong> have all been shown to reduce the severity of depressive symptoms in BD patients. Except for fluoxetine when combined with olanzapine, no antidepressant is explicitly approved by the FDA for bipolar depression treatment.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Antidepressant monotherapy is discouraged in bipolar I disorder, mainly when mixed features are present and even when combined with a mood stabiliser. ECT, repetitive transcranial magnetic stimulation, deep brain stimulation, vagus nerve stimulation, lifestyle interventions, and psychotherapies are examples of non-pharmacological treatments for bipolar depression.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Apart from these, some FDA-approved drugs such as <strong>Olanzapine\u2010fluoxetine combination (OFC), Quetiapine, Lurasidone, and Cariprazine<\/strong> are also used for Bipolar Depression treatment.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bipolar Depression Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Bipolar Depression market size is anticipated to grow at a <strong>CAGR of 11.9%<\/strong> during the study period (2017-30). Furthermore, the Bipolar Depression treatment space will see a significant impact in the coming years as treatment improves over time along with the launch of novel therapies such as <strong>Caplyta, NRX-100\/NRX-101, SEP-4199,<\/strong> and others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">For more information on the market outlook of bipolar depression, visit <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bipolar-disorder-manic-depression-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Bipolar Depression Market Size<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bipolar Depression Pipeline Therapies and Key Companies<\/strong>&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Caplyta (Lumateperone; ITI-007): Intra-Cellular Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">NRX-100\/NRX-101: NeuroRx<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rexulti\/Rxulti (Brexpiprazole): Otsuka\/ Lundbeck<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">SEP-4199: Sunovion (Sumitomo Dainippon Pharma)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">COMP 360 (Psilocybin Therapy): COMPASS Pathways<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Falkieri (Esketamine DPI): Celon Pharma<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bipolar Depression Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Future Directions in Blood Biomarkers<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Increase in Awareness and Technology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Advances Toward Precision Medicine for BD<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bipolar Depression Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Misdiagnosis of Bipolar Depression<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Unsatisfactory Design of RCTs<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Limited Understanding of the Disease Mechanism<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the Report<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bipolar Depression Key Companies:<\/strong> Intra-Cellular Therapies, NeuroRx, Otsuka, Lundbeck, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, Celon Pharma, among others.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bipolar Depression Key Pipeline Therapies:<\/strong> Caplyta (Lumateperone; ITI-007), NRX-100\/NRX-101, Rexulti\/Rxulti (Brexpiprazole), SEP-4199, COMP 360 (Psilocybin Therapy), Falkieri (Esketamine DPI), and others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bipolar Depression Segmentation:<\/strong> By Geography, By Bipolar Depression therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis:<\/strong> Comparative and conjoint analysis of Bipolar Depression emerging therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Tools Used:<\/strong> SWOT Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Case Studies<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>KOL&rsquo;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analyst&rsquo;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"89\" \/>\n<col width=\"535\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\">1.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Key Insights<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">2.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">3.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Bipolar Depression Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">4.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Executive Summary of Bipolar Depression<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">5.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Bipolar Depression Epidemiology and Market Methodology<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">6.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Bipolar Depression Disease Background and Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">7.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Diagnosis of Bipolar Disorder<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">8.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Current Treatment Practices of Bipolar Disorder<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">9.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Bipolar Depression Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">10.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Bipolar Depression The United States<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">11.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Bipolar Depression EU-5<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">12.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Bipolar Depression Japan<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">13.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Bipolar Depression Patient Journey<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">14.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Key Endpoints in Bipolar Depression Clinical Trials<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">15.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Bipolar Depression Marketed Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">16.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Bipolar Depression Emerging Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">17.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Bipolar Depression: 7 Major Market Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">18.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Bipolar Depression The United States Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">19.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Bipolar Depression EU-5 Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">20.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Bipolar Depression Japan<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">21.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Bipolar Depression Market Access and Reimbursement<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">22.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Bipolar Depression Market Drivers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">23.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Bipolar Depression Market Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">24.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">25.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Bipolar Depression Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">26.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">27.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">28.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">29.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get in touch with our business executive for <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Healthcare Due Diligence Services<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Major Depressive Disorder Market<\/a><\/strong>&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get a comprehensive analysis of Familial Hypercholesterolemia pipeline therapies and key companies such as <strong>Takeda Pharmaceuticals, Forest Laboratories, Otsuka Pharmaceuticals, Janssen Research &amp; Development, Axsome Therapeutics, Fabre-Kramer Pharmaceuticals, SAGE Therapeutics,<\/strong> among others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=the-bipolar-depression-market-is-growing-at-a-cagr-of-119-driven-by-the-potential-pipeline-therapies-during-the-study-period-201730-in-the-7mm\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=the-bipolar-depression-market-is-growing-at-a-cagr-of-119-driven-by-the-potential-pipeline-therapies-during-the-study-period-201730-in-the-7mm\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bipolar Depression Market The Bipolar Depression treatment space will see a significant impact in the coming years as treatment improves over time along with the launch of novel therapies. DelveInsight&rsquo;s Bipolar Depression market report provides thorough comprehension of Bipolar Depression, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/the-bipolar-depression-market-is-growing-at-a-cagr-of-119-driven-by-the-potential-pipeline-therapies-during-the-study-period-201730-in-the-7mm_576277.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-576277","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/576277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=576277"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/576277\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=576277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=576277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=576277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}